Shanghai Qingrun Pharmaceutical Technology

Shanghai Qingrun Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in China, specializing in the development of innovative small molecule therapies for metabolic and endocrine diseases. The company's primary focus is on next-generation treatments for type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). Its lead programs include multi-agonist small molecules targeting the GLP-1, GIP, and glucagon receptors, designed to provide oral alternatives to injectable peptide therapies. By leveraging advanced drug design, Qingrun aims to address significant unmet needs in the global metabolic health market.